Slide 1: Analyst / Investor Conference FY 2013 Results and Guidance FY 2014
Analyst / Investoy Confevence FY 2013 Results and Guidance Fy 2014 Febvuavy (3, 2014 03.00 pm. CET Uwe Rahvhoff, CEO Rainey Beaujean, CFO
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Agenda
Agenda Review FY 2013 Uwe Röhrhoff, CEO Financial Overview FY 2013 Rainer Beaujean, CFO Guidance FY 2014 Uwe Röhrhoff, CEO 3
Slide 4: FY 2013: Positive development of key metrics
FY 2013: Positive development of key metrics Key Group figures in EUR m, EPS and dividend in EUR Revenues adjusted EBITDA FXN: + 5.8% FY 2013 FXN: EUR 254.0m + 3.8% + 4.1% 19.7% Margin 19.7% adjusted EPS Dividend per share + 17.6% + 7.7% Proposed * Retrospective restatement due to the early adoption
Slide 5: Key growth projects and market dynamics 2013
Key growth projects and market dynamics 2013 Pharma Continued trend towards self-medication Higher prevalence of diabetes and respiratory diseases driving demand for drug-delivery devices Quality, reliability, innovation key for drug packaging Cosmetics: Continued trend towards high-qualit
Slide 6: FY 2013 targets fully achieved
FY 2013 targets fully achieved Confirmed Guidance Actual results FY 2013 as of Oct 2, 2013 FY 2013 Revenues + 5% to 6% at const. FX1 + 5.8% at const. FX Adj. EBITDA Range of EUR 245m to EUR 250m at const. FX EUR 254.0m2 at const. FX Capex Around 9% to 10% of revenues 9.4% 1 Average exchange ra
Slide 7: Agenda
Agenda Review FY 2013 Uwe Röhrhoff, CEO Financial Overview FY 2013 Rainer Beaujean, CFO Guidance FY 2014 Uwe Röhrhoff, CEO 7
Slide 8: FY 2013: Revenues by division
FY 2013: Revenues by division FY 2013 FY 2012 Change Change in % at EUR m EUR m in % const. FX1 Total Group 1,265.9 1,219.1 +3.8 +5.8 Plastic Systems 463.6 427.2 +8.5 +12.2 Moulded Glass 387.7 372.8 +4.0 +4.9 Tubular Glass 342.8 333.8 +2.7 +3.6 Life Science Research 86.8 99.6 -12.9 -10.9 1 Currency
Slide 9: FY 2013: Adjusted EBITDA and margin by division
FY 2013: Adjusted EBITDA1 and margin by division FY 2013 Pro forma2 FY 2012 Margin Margin EUR m in % EUR m in % Total Group 249.8 19.7 239.9 19.7 Plastic Systems 109.9 23.7 92.9 21.8 Moulded Glass 85.0 21.9 81.6 21.9 Tubular Glass 63.9 18.6 70.2 21.0 Life Science Research 11.5 13.2 13.5 13.6 1 Earni
Slide 10: Key balance sheet and cash flow figures
Key balance sheet and cash flow figures Nov 30, 2013 Nov 30, 2012 Change EUR m Pro forma2 EUR m in % Total assets 1,615.8 1,555.9 +3.8 Equity 563.4 538.2 +4.7 Equity ratio in % 34.9 34.6 Net working capital1 201.9 175.2 +15.2 in % of LTM revenues 15.9 14.4 FY 2013 FY 2012 Change EUR m EUR m in % Cap
Slide 11: Long-term financing structure with ample financial leeway
Long-term financing structure with ample financial leeway Debt/cash positions Nov 30, 2013 Nov 30, 2012 Change in EUR m EUR m EUR m in % Bond 300.0 300.0 unch. Long-term bank debt 106.7 135.8 -21.4 Revolving bank debt 68.8 0.0 n/a Local borrowings and leasing 14.2 16.8 -15.5 Total financial debt 489
Slide 12: Agenda
Agenda Review FY 2013 Uwe Röhrhoff, CEO Financial Overview FY 2013 Rainer Beaujean, CFO Guidance FY 2014 Uwe Röhrhoff, CEO 12
Slide 13: Gerresheimer: Former structure until Nov 30, 2013
Gerresheimer: Former structure until Nov 30, 2013 Production technology focus with 4 divisions (2007-2013) Life Science Plastic Systems Tubular Glass Moulded Glass Research Andreas Schütte Uwe Röhrhoff Uwe Röhrhoff Rainer Beaujean 13
Slide 14: Gerresheimer: New divisional setup effective from Dec 1, 2013
Gerresheimer: New divisional setup effective from Dec 1, 2013 Customer-focussed organization with 3 divisions Life Science Plastics & Devices Primary Packaging Glass Research Andreas Schütte Uwe Röhrhoff Rainer Beaujean 14
Slide 15: Reconciliation: From former to new structure
Reconciliation: From former to new structure; FY 2013 figures in EUR m Tubular Glass Life Science Plastic Systems Moulded Glass Syringes Tubing/Conv. Research Revenues: 463.6 Revenues: 98.2 Revenues: 244.6 Revenues: 387.7 Revenues: 86.8 adj. EBITDA: 109.9; adj. EBITDA: 10.9 adj. EBITDA: 53.0 adj. EB
Slide 16: Guidance FY 2014
Guidance1) FY 2014 Revenues +4% to 6% at const. FX EUR 250m to EUR 265m Adj. EBITDA at const. FX 9% to 10% of revenues Capex at const. FX 1 Based on (budgeted) exchange rate assumption for FY 2014 of EUR 1.00 = USD 1.30 16
Slide 17: Capital Markets Day 2014
Capital Markets Day 2014 Date October 8+9, 2014 Location Gerresheimer Buende, Germany Registration Invitations will be sent out shortly 17
Slide 18: Financial Calendar
Financial Calendar April 10, 2014 Interim Report 1st Quarter 2014 April 30, 2014 Annual General Meeting 2014 July 10, 2014 Interim Report 2nd Quarter 2014 October 8, 2014 Interim Report 3rd Quarter 2014 18
Slide 19: Investor Relations & Creditor Relations contact details
Investor Relations & Creditor Relations contact details Phone +49 211 6181-257 Fax +49 211 6181-121 E-mail gerresheimer.ir@gerresheimer.com IR website www.gerresheimer.com/ir 19
Slide 20: Backup
GERRESHEIMER Backup
Slide 21: FY 2013 P&L overview
FY 2013 P&L overview FY 2013 FY 2012 Pro forma3 Change EUR m EUR m in % Revenues 1,265.9 1,219.1 +3.8 Adjusted EBITDA1 249.8 239.9 +4.1 Restructuring expense 4.8 0.0 n/a One-off income/expense -3.8 -5.5 +30.9 EBITDA 241.2 234.4 +2.9 Amortization of FV adjustments 19.0 18.0 +5.6 Depreciation and amor
Slide 22: Q4 2013 P&L overview
Q4 2013 P&L overview Q4 2013 Q4 2012 Pro forma3 Change EUR m EUR m in % Revenues 325.2 324.9 +0.1 Adjusted EBITDA1 82.4 73.7 +11.8 Restructuring expense 4.8 0.0 n/a One-off income/expense -3.5 -0.8 >-100 EBITDA 74.1 72.9 +1.6 Amortization of FV adjustments 5.4 4.6 +17.4 Depreciation and amortization
Slide 23: Q4 2013: Revenues by division
Q4 2013: Revenues by division Q4 2013 Q4 2012 Change Change in % at EUR m EUR m in % const. FX1 Total Group 325.2 324.9 +0.1 +3.2 Plastic Systems 119.8 116.9 +2.5 +7.4 Moulded Glass 99.9 101.6 -1.7 -0.1 Tubular Glass 88.7 87.8 +1.0 +3.2 Life Science Research 20.4 22.3 -8.5 -4.2 1 Currency effects ar
Slide 24: Q4 2013: Adjusted EBITDA and margin by division
Q4 2013: Adjusted EBITDA1 and margin by division Q4 2013 Pro forma2 Q4 2012 Margin Margin EUR m in % EUR m in % Total Group 82.4 25.3 73.7 22.7 Plastic Systems 37.8 31.6 28.1 24.0 Moulded Glass 26.0 26.0 24.6 24.2 Tubular Glass 20.3 22.9 21.7 24.7 Life Science Research 3.1 15.2 3.7 16.6 1 Earnings b
Slide 25: Adjusted EBITDA Q4 2012 and FY 2012 bridge to pro forma IAS 19
Adjusted EBITDA Q4 2012 and FY 2012-Bridge from reported to pro forma figures in accordance with IAS 19 revised Pro forma in EUR m Q4 2012 Adjustment Q4 2012 Adjusted EBITDA Plastic Systems 28.0 0.02 28.0 Moulded Glass 24.7 -0.05 24.7 Tubular Glass 21.1 0.61 21.7 Life Science Research 3.7 0.00 3.7 S
Slide 26: Development of Working Capital
Development of Working Capital1 Nov 30, 2013 Nov 30, 2012 Nov 30, 2011 EUR m EUR m EUR m Inventories 194.5 189.0 159.9 thereof prepayments made 14.0 12.4 13.9 Trade receivables 192.6 179.4 162.8 Trade payables 127.0 154.3 119.2 Payments received on account of orders 58.2 38.9 31.0 Net Working Capita
Slide 27: Development of Inventories
Development of Inventories Nov 30, 2013 Nov 30, 2012 Nov 30, 2011 EUR m EUR m EUR m Raw materials, con- sumables and supplies 48.8 45.1 43.2 Work in progress 33.1 27.9 15.1 Finished goods and merchandise 98.6 103.6 87.7 Prepayments made 14.0 12.4 13.9 Inventories 194.5 189.0 159.9 27